The international pharmacy chain Dr. Max has received the Competition Council approval for the acquisition of A&D Pharma Group, via GLEBI HOLDINGS PLC. Following the Competition Council announcement, Dr. Max will become the majority shareholder of A&D Pharma Group. A&D Pharma Group holds the Sensiblu and Punkt pharmacy chains, the drug distributor Mediplus and A&D Pharma Marketing & Sales. The last remaining formal steps will be completed in the coming weeks.
Dr. Max has entered the Romanian market in June 2017, following the acquisition of Arta pharmacies chain, consisting in 31 pharmacies. Through the current transaction, Dr. Max will become a major player on the Romanian market with a total number of 613 pharmacies. This figure does not include the 18 Arta pharmacies that will be divested according to the commitment made to the Competition Council. Dr. Max will also hold a full-line wholesale business in this industry and a key Marketing & Sales service provider, with more than 5,000 employees.
“The acquisition of A&D Pharma marks a new milestone for Dr. Max on the Romanian Market. This acquisition represents a concrete expression of our commitment to Romania as well as of our long term development plans at regional level. Dr. Max becomes one of the top players in Europe having a leading position on the majority of the markets where is present up to today (Czech Republic, Slovakia, Romania, Poland, Serbia and Italy). We will strengthen A&D Pharma operations, further promoting on the Romanian market the elements that have positioned Dr. Max corporate brand as a true international industry standard: services to patients and customers, large products range and accessibility” has underlined Leonardo Ferrandino, CEO Dr. Max.
“Through vision and dedication we were able to build a successful business over the past 23 years. We have now assured a broader, international future for A&D and our employees by bringing the company in Dr. Max. We will work together to maximize this opportunity that creates value for patients, doctors and employees” declared Robert Popescu, CEO A&D Pharma.
Through this transaction, Dr. Max will operate at international level, over 2,000 pharmacies in Central and Eastern Europe, with over EUR 2.3 billion sales. The company will have more than 12.000 employees in Europe.
Dr. Max is owned by Penta Investments, a long term investor mainly in Central and Eastern Europe, with assets in healthcare, financial services, manufacturing, defense, retail, real estate development and media. Penta Investments is committed to continue to successfully develop healthcare projects in Central and Eastern Europe. In 2017, companies in the Penta Investments portfolio controlled combined assets worth EUR 9 billion and employed over 41,000 people.
Dr. Max is a leading pharmacy chain in the CEE region and at EU level in general. The company is becoming a unique European player providing innovative ways to address health and wellbeing applying an omnichannel set-up.
More on: http://www.drmaxpharma.com
About Penta Investments
Penta is a Central European investment group established in 1994. The group operates in the healthcare system, in financial services, manufacturing, retail, real estate development and media businesses. Penta operates in more than ten European countries and has offices in Prague, Bratislava and Warsaw.
More on: www.pentainvestments.com
About A&D Pharma
A&D Pharma Group brings health closer to people, offering integrated services for the import, distribution, marketing and retail of pharmaceuticals, through its pharmaceutics distribution division Mediplus, pharmacy chains Sensiblu and Punkt, and the A&D Pharma Marketing&Sales division. The Group has a 23-year history in the market. The overall turnover for 2016 exceeded EUR 1 billion.
More on: www.adpharma.com